Pancreatic cancer yakanangana nemushonga, pancreatic cancer BRCA mutation yakanangwa mushonga olaparib (Olaparib, Liprot Lynparza) yakagamuchira FDA nyanzvi rutsigiro.
Nekuda kwekupindirwa kwakasimba uye kushomeka kwekurapa kwegomarara repancreatic, hapana kurapa kwekutanga kwakaunzwa mumakumi mashoma emakore apfuura, uye varwere vane advanced cancer cancer vanoda nekukurumidza mishonga mitsva uye marapirwo. Pasi rose, kuitika kwegermline BRCA shanduko mukenza yepancreatic ndeye 5-7%.
The targeted drug olapaly, which specifically targets BRCA mutations, has achieved excellent clinical data in the maintenance treatment of pancreatic cancer, which is enough to improve the current clinical treatment and help patients with advanced pancreatic cancer prolong their survival. Muna Gumiguru 2018, iyo US Chikafu neDrug Administration (FDA) yakapa olapaly nherera kurapwa kwechirwere chepancreatic cancer
Olaparib inotsigirwa neiyo FDA nyanzvi komiti yekurapa gBRCAm pancreatic cancer
Musi waZvita 17, US Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) yakavhota 7 kusvika 5 kuti ikurudzire kubvumidzwa kwemushonga wakanangana nechirwere chegomarara Lynparza (zita reChinese brand: Liprot, generic name) : Olaparib, olaparib), seyekutanga mutsara wekuchengetedza monotherapy, kurapwa kwevarwere vane metastatic pancreatic cancer vasina kufambira mberi mushure mekugamuchira yekutanga-mutsara platinamu chemotherapy kweanosvika mavhiki gumi nematanhatu uye inotakura germline BRCA mutation (gBRCAm).
Kuendeswa kwesNDA kunoenderana nemhedzisiro yakanaka yemuyedzo wePOLO chikamu chechitatu chakaburitswa muNew England Journal of Medicine uye yakaburitswa pamusangano wepagore we3 American Society of Clinical Oncology (ASCO). Mhedzisiro yacho yakaratidza kuti nhamba uye yekiriniki kukosha kwekufambira mberi-isina kupona (PFS) kwakagadziridzwa zvakanyanya, kuderedza njodzi yekuenderera kwechirwere kana kufa ne2019%.
Olaparib yakapetwa kakapetwa nguva yekuenderera-yemahara yekurarama kwevarwere vane metastatic pancreatic cancer ine BRCA shanduko (3.8 vs 7.4 mwedzi).
Olapali has been approved by the US FDA for the treatment of ovarian and kenza yebonde. Olaparib was approved by the US FDA in December 2014 to become the first PARP inhibitor approved globally, and has been approved in 65 countries around the world.
The good news is that Olapali has been approved for listing in China for the treatment of ovarian kenza, and was included in the medical insurance catalog at the end of November this year. The price of drugs has dropped by about 60%. After the price reduction, it should be less than 10,000 yuan per box. According to 70% of medical insurance reimbursement, the price of each box of olapaly is almost 3,000 yuan, and the monthly cost of medication is 6,000 yuan.
Zviratidzo zviviri zveOlapali
Muna Nyamavhuvhu 2018, Olapali yakatenderwa kunyoreswa muChina, ichiva chinwiwa chekutanga chakanangwa neChina chekenza yeovari, inoshandiswa pakurapa gomarara rinowanzoitika replatin-inonzwisisika (chirwere chakatsiga mushure mekurapwa kweplatinamu, Ola Pali anogona kunonoka nguva yekudzokazve).
Musi waZvita 5, 2019, China’s State Drug Administration has officially approved the use of olapa for first-line maintenance treatment of patients with BRCA-mutated advanced ovarian cancer. Benefiting from China’s vigorous support for pharmaceutical innovation and the accelerated advancement of clinically needed new drug approvals, olapaly became the first PARP inhibitor approved in China for first-line maintenance therapy of ovarian cancer.
Zviratidzo zveOlapali zvinogamuchirwa neUS FDA
Chekutanga-mutsara kugadziriswa kwekurapa kwepamberi ovari kenza ine BRCA shanduko
Kuchengetedza kurapwa kwevakuru varwere vane zvinokuvadza kana kufungidzirwa zvinokuvadza germline kana somatic BRCA shanduko (g BRCAm kana s BRCA m) muvakuru varwere vane epithelial ovarian cancer, fallopian tube kenza kana yekutanga peritoneal kenza Mhinduro yakazara kana kukwana mhinduro. Sarudza varwere kuti varapwe zvichibva pane FDA yakatenderwa LYNPARZA inogadzirisa kuongororwa.
Kuchengetedza kurapwa kwechirwere chekenza chinowanzoitika
Nekurapa kwekurapa kwevakuru varwere vane dzokororo epithelial ovarian cancer, fallopian tube kenza, kana yekutanga peritoneal cancer, ava varwere vane yakakwana kana kukwana mhinduro kune platinamu-based chemotherapy.
Postline kurapwa kweakakwira BRCA mutation ovarian cancer
Nekurapa kwevakuru varwere vane ovarian cancer ine zvinokuvadza kana kufungidzirwa zvinokuvadza germline BRCA shanduko (g BRCA m), ivo vakagamuchira 3 kana kupfuura kumberi kwemakemikari ekurapa. Sarudza varwere kuti varapwe zvichibva pane FDA inogamuchirwa LYNPARZA oncomitant kuongororwa.
BRCA shanduko, HER2-isina metastatic kenza yemazamu kurapwa
Kurapwa kwegomarara rezamu remazamu nekukuvadza kana kunofungidzirwa kukuvadza germline BRCA mutations (g BRCA m), munhu epidermal growth factor receptor 2 (HER2) negative, iyo yakarapwa neoadjuvant therapy, adjuvant therapy, kana metastatic cancer. Varwere vane gomarara rezamu avo vari mahormone receptor (HR) akanaka vanofanirwa kutanga vawana endocrine therapy, kana kunzi haina kukodzera endocrine therapy. Sarudza varwere kurapwa zvichienderana neFDA yakatenderwa LYNPARZA concomitant diagnosis.
Olapali is a first-in-class, oral PARP inhibitor that utilizes defects in the DNA repair pathway to preferentially kill cancer cells. This mode of action gives Olapali the potential to treat a wide range of tumors with DNA repair defects. Currently approved for ovarian cancer and breast cancer, it is expected to be quickly approved for pancreatic cancer, and has achieved excellent results in the treatment of Kenza yeprotate.
Mukutaura, chinangwa chePARP inhibitors ndiyo BRCA mutant gene, ingave inogamuchirwa kenza yeovarian, gomarara repazamu, kana gomarara repancreatic iro richangogamuchira FDA nyanzvi yekutsigira, mukuwedzera pakurapa kenza inowanzoitika yeovarian, yakakodzera Ola Varwere veparley vanofanirwa kuona shanduko mu BRCA geni uye havagone kuishandisa zvisina basa.
Nokudaro, zvakakosha zvikuru kuwana mishumo yakarurama uye ine chiremera chekuongorora mazita asati arapwa. Chete kana iyo BRCA gene mutation bvunzo mhinduro dzakarurama ndipo tinogona kutarisira kuwana mabhenefiti ekupona. Iwo ma genetic test institution parizvino ari pamusika anosiyana zvakanyanya. Vicki anokurudzira kuti utarise kuvimbika kweiyo genetic test institution kubva kune zvinotevera zvinhu.
Kutanga, iyo Hardware-iyo yekuona michina inofanirwa kuve chaiyo, uye iyo data iri chaiyo!
Chechipiri, iyo software-database uye simba rehunyanzvi ndiwo musimboti wemakwikwi!
Yetatu, kudzora kwemhando-saizi yetimu yekuyedza inosarudzika iko kwechokwadi kwemhedzisiro yemiedzo!
Chechina, rabhoritari-inofanirwa kuwana zvedzidzo yenyika (dzenyika dzese), CAP uye CLIA mbiri chitupa!
Chechishanu, kuzivikanwa kwepamutemo-sarudza FDA inobvumidza kuyedzwa kwemajini kwakachengeteka.
